Intermolecular, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2017. For the quarter, the company reported total revenue of $8,622,000 against $10,574,000 a year ago. Loss from operations was $1,962,000 against $6,912,000 a year ago. Loss before provision for income taxes was $1,828,000 against $6,772,000 a year ago. Net loss was $1,828,000 against $6,775,000 a year ago. Net loss per share, basic and diluted was $0.04 against $0.14 a year ago. Adjusted EBITDA was $116,000 against adjusted LBITDA of $932,000 a year ago. GAAP operating loss was $1,962,000 against $6,912,000 a year ago. Non-GAAP operating loss was $1,720,000 against $6,026,000 a year ago.

For the quarter, the company reported total revenue of $26,655,000 against $36,821,000 a year ago. Loss from operations was $10,943,000 against $12,764,000 a year ago. Loss before provision for income taxes was $10,518,000 against $12,437,000 a year ago. Net loss was $10,519,000 against $12,444,000 a year ago. Net loss per share, basic and diluted was $0.21 against $0.25 a year ago. Net cash used in operating activities was $1,175,000 against $1,700,000 a year ago. Purchase of property and equipment was $705,000 against $2,130,000 a year ago. Adjusted LBITDA was $2,759,000 against $796,000 a year ago. Adjusted LBITDA was $2,759,000 against $796,000 a year ago. GAAP operating loss was $10,943,000 against $12,764,000 a year ago. Non-GAAP operating loss was $9,722,000 against $9,828,000 a year ago.

For the fourth quarter, the company expects Intermolecular projects revenue in the range of $9.4 million to $9.9 million. GAAP net loss is projected between $1.0 million and $1.5 million, or between $0.02 to $0.03 per share, on approximately 49.6 million shares outstanding. Non-GAAP net loss, which excludes stock-based compensation expense, is projected between $0.7 million and $1.2 million, or between $0.01 to $0.03 per share. Adjusted EBITDA is projected to be between $0.5 million and $1.0 million.